Starpharma Holdings

Starpharma Holdings Current Assets

The Current Assets of Starpharma Holdings (SPL.AX) as of Nov 4, 2026 is 13.19 M AUD. In the previous year, Current Assets was 22.56 M AUD — a change of -41.53% (lower).

Current Assets

13.19 MAUD

YoY

-41.53%

Last updated:

Current Assets of Starpharma Holdings is 2026 13.19 M AUD. Current Assets of Starpharma Holdings was 2025 22.56 M AUD. It decreases by -41.53% lower compared to the previous year.

The Starpharma Holdings Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
52.93 M AUD
Jan 1, 2020
36.68 M AUD
Jan 1, 2021
70.76 M AUD
Jan 1, 2022
60.66 M AUD
Jan 1, 2023
47.12 M AUD
Jan 1, 2024
32.92 M AUD
Jan 1, 2025
22.56 M AUD
Jan 1, 2026
13.19 M AUD
The Starpharma Holdings Current Assets history
YEARCurrent AssetsYoY
13.19 MAUD-41.53%
22.56 MAUD-31.47%
32.92 MAUD-30.14%
47.12 MAUD-22.32%
60.66 MAUD-14.27%
70.76 MAUD+92.92%
36.68 MAUD-30.71%
52.93 MAUD-8.17%
57.64 MAUD-12.73%
66.05 MAUD+30.88%
50.46 MAUD+43.26%
35.23 MAUD+22.28%
28.81 MAUD-26.75%
39.33 MAUD-12.35%
44.87 MAUD+125.00%
19.94 MAUD-17.69%
24.23 MAUD+83.89%
13.18 MAUD+48.33%
8.88 MAUD-19.06%
10.97 MAUD-35.24%
16.94 MAUD+103.87%
8.31 MAUD-47.30%
15.77 MAUD+96.18%
8.04 MAUD-54.82%
17.79 MAUD-30.18%
25.48 MAUD-9.75%
28.24 MAUD—
0.00AUD—
0.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Starpharma Holdings Stock analysis

What does Starpharma Holdings do? Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Starpharma Holdings stock

Current Assets of Starpharma Holdings is 13.19 M AUD in 2026.

Current Assets of Starpharma Holdings changed from 22.56 M AUD to 13.19 M AUD, representing a -41.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Starpharma Holdings since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Starpharma Holdings historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Starpharma Holdings

All Key Metrics — Starpharma Holdings